XXXX implants in the treatment of @entity158 in @entity46 .

@entity1 @entity7458 @entity1834 @entity604 @entity2371 @entity53 @entity530 @entity46 @entity158 @entity546 @entity2588
OBJECTIVE: To examine the treatment of @entity158 in @entity46 by @entity7458 implants. DESIGN: Fourteen @entity1 with laparoscopically confirmed @entity530 were included in the study. All presented with severe @entity1834 with or without deep @entity546 and @entity2371 . @entity7458 6.6 mg. Implants were injected subcutaneously in the lateral region of the anterior abdominal wall, 3 doses every 8 weeks in group 1 (n=7) and 2 doses every 12 weeks in group 2 (n=7). Bone mineral density (BMD) was measured at the lumbar spine by dual energy X-ray absorptiometry (DEXA) before initiation of treatment and 1 year after. Symptoms, pelvic examination, ultrasonogram and serum @entity53 were recorded every 4 weeks until two regular menses were established. RESULTS: All the painful symptoms were relieved and eventually disappeared in every @entity1 within 4-6 weeks. Mean duration of @entity2588 in group 1 (408.4+/-47.7 days) was significantly longer than group 2 (331.3+/-22.4 days), p < 0.01. Mean duration of first observed side effects was 2.7+/-1.6 weeks. Hot flushes were the most common side effects. Serum @entity53 levels were below 15 pg/ml in all @entity1 and there were no significant differences between the two groups during @entity2588 . There was significant @entity604 in both groups, 6.49+/-4.90 per cent in group 1 and 7.71+/-5.67 per cent in group 2. However, there were no significant differences between the two groups for lumbar BMD before and after treatment. CONCLUSION: @entity7458 implants are effective in the treatment of @entity158 in @entity46 . These implants should have an important clinical application when chronic treatment is indicated. Further study is needed to design how this preparation should be used to minimize the adverse effects.
